Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes

Biomaterials

Volumn 25, Issue 26, 2004, Pages 5681-5703

  Gorbet, Maud B ^a   Sefton, Michael V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomaterials; CD11b; Coagulation; Complement activation; Leukocytes; Platelets; Thrombosis; Tissue Factor

Indexed keywords

ACTIVATION ANALYSIS; ADHESION; BLOOD; COAGULATION; TISSUE;

INFLAMMATION; PLATELETS;

BIOMATERIALS;

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTISTATIN; BENZAMIDINE; BIOMATERIAL; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; COMPLEMENT; CYTOKINE; ENDOTOXIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; PADGEM PROTEIN; PENTAMIDINE; POLYACRYLONITRILE; PROPERDIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1; WARFARIN; XIMELAGATRAN;

ANTIGEN ANTIBODY COMPLEX; BIOLOGY; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL GRAFT; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; DEVICE; DISEASE ASSOCIATION; HUMAN; HYPOTENSION; INFLAMMATION; LEUKOCYTE; LEUKOPENIA; LUNG INJURY; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS;

BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COMPLEMENT SYSTEM PROTEINS; HUMANS; LEUKOCYTES; PLATELET ACTIVATION; PROSTHESES AND IMPLANTS; THROMBOSIS;

EID: 2442501409     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2004.01.023     Document Type: Review

References (259)

1. Hanson S.R. Device thrombosis and thromboembolism. Cardiovasc Pathol. 2:1993;157S-165S
2. Bittl J.A. Coronary stent occlusion. thrombus horribilis J Am Coll Cardiol. 28:1996;368-370
3. Clagett G.P., Eberhart R.C. Artificial devices in clinical practice. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis: basic principles and clinical practice. 1994;1486-1505 Lippincott, Philadelphia
4. Bick R.L. Hemostasis defects with cardiac surgery, general surgery and prosthetic devices. Bick R.L. Disorders of hemostasis and thrombosis. 1992;195-222 American Society of Clinical Pathologist Press, Chicago
5. Eberhart R.C., Clagett C.P. Catheter coatings, blood flow, and biocompatibility. Semin Hematol. 28:1991;42-48
6. Edmunds L.H.J. Is prosthetic valve thrombogenicity related to design or material? Tex Heart Inst J. 23:1996;24-27
7. Geiser T., Sturzenegger M., Genewein U., Haeberli A., Beer J.H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral emboli and platelet microparticles in patients with prosthetic heart valves. Stroke. 29:1998;1770-1777
8. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty. a mechanism for recurrent disease? J Am Coll Cardiol. 28:1996;345-353
9. Wendel H.P., Ziemer G. Coating techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg. 16:1999;342-350
10. Defraigne J.O., Pincemail J., Larbuisson R., Blaffart F., Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 69:2000;1084-1091
11. Moen O., Hogasen K., Fosse E., et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg. 63:1997;105-111
12. Baufreton C., Jansen P.G., Le B.P., et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg. 63:1997;50-56
13. Muehrcke D.D., McCarthy P.M., Kottke-Marchant K., et al. Biocompatibility of heparin-coated extracorporeal bypass circuits. a randomized, masked clinical trial J Thorac Cardiovasc Surg. 112:1996;472-483
14. Gorman R.C., Ziats N., Rao A.K., et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:1996;1-11
15. Redmond J.M., Gillinov A.M., Stuart R.S., et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg. 56:1993;474-478
16. Levy M., Hartman A.R. Heparin-coated bypass circuits in cardiopulmonary bypass. improved biocompatibility or not Int J Cardiol. 53:1996;S81-S87
17. Fosse E., Thelin S., Svennevig J.L., et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes. a European multicentre study Eur J Cardiothorac Surg. 11:1997;320-327
18. Videm V., Mollnes T.E., Bergh K. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg. 117:1999;803-809
19. Janvier G., Baquey C., Roth C., Benillan N., Belisle S., Hardy J-.F. Extracorporeal circulation, hemocompatibility and biomaterials. Ann Thorac Surg. 62:1996;1926-1934
20. Videm V., Mollnes T.E., Fosse E. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in high risk population. J Thorac Cardiovasc Surg. 117:1999;794-802
21. Gillinov A.M., DeValeria P.A., Winkelstein J.A., et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg. 55:1993;619-624
22. Fitch J.C., Rollins S., Matis L., et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 100:1999;2499-2506
23. Murkin J.M. Cardiopulmonary bypass and the inflammatory response; a role for serine protease inhibitor. J Cardiothorac Vasc Anesth. 11:1997;19-23
24. Sundaram S., Gikakis N., Hack C.E., et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost. 75:1996;76-82
25. Rao A.K., Sun L., Gorman J.H., Edmunds L.H. Jr. GPIIb/IIIa receptor antagonist Tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost. 82:1999;140-144
26. Vertress R.A., Tao W., Kramer G.C., et al. Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte populations during cardiopulmonary bypass. ASAIO J. 40:1994;M554-M559
27. Schmaier A.H. Contact activation. a revision Thromb Haemost. 77:1997;101-107
28. Furie B., Furie B.C. The molecular basis of blood coagulation. Cell. 53:1988;505-518
29. Blajchman M.A., Özge-Anwar A.H. The role of the complement system in hemostasis. Prog Hematol. XIV:1986;149-182
30. Jetsy J., Nemerson Y. The pathways of blood coagulation. Beutler E., Lichtman M.A., Coller B.S., Kipps T.J. Williams hematology. 5th ed:1995;1227-1238 McGraw-Hill, New York
31. Rapaport S.I., Rao V.M. Initiation and regulation of the tissue factor-dependent blood coagulation. Arterioscler Thromb. 12:1992;1111-1121
32. Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744
33. Osterud B., Rapaport S.I. Activation of Factor IX by the reaction product of tissue factor and Factor VIIa; additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 74:1977;5260-5264
34. Lawson J.H., Kalafatis M., Stram S., Mann K.G. A model for the tissue factor pathway to thrombin. An empirical study. J Biol Chem. 269:1994;23357-23366
35. Rand M.D., Lock J.B., van't Veer C., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;3432-3445
36. Bauer K.A., Rosenberg R.D. Control of coagulation factors. Beutler E., Lichtman M.A., Coller B.S., Kipps T.J. Williams hematology. 5th ed:1995;1239-1250 McGraw-Hill, New York
37. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 324:1991;1865-1875
38. Novotny W.F., Girard T.J., Miletich J.P., Broze G.B. Jr. Platelets secrete a coagulation inhibitor functionally and antigenetically similar to the lipoprotein associated coagulation inhibitor. Blood. 72:1988;2020-2025
39. McGee M.P., Foster S., Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control blood coagulation. J Exp Med. 179:1994;1847-1854
40. Cooke E.D., Bowcock S.A., Lloyd M.J., Pilcher M.J. Intravenous lignocaine in prevention of deep venous thrombosis after elective surgery. The Lancet. ii:1977;797-799
41. Higuchi D.A., Wun T.C., Likert K.M., Broze G.J. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood. 79:1992;1712-1719
42. Esmon C.T. Regulatory mechanisms in hemostasis: natural anticoagulants. Colman R.W.et al, Hemostasis and thrombosis. 1997;1597-1599 Lippincott, Philadelphia
43. Horbett T.A. Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials. Cardiovasc Pathol. 2:1993;137S-148S
44. Ziats N., Pankowsky D.A., Tierney B.P., Ratnoff O.D., Anderson J.M. Adsorption of Hageman Factor (Factor XII) and other human plasma proteins to biomedical polymers. J Lab Clin Med. 116:1990;687-696
45. Mulzer S.R., Brash J.L. Identification of plasma proteins adsorbed to hemodialyzers during clinical use. J Biomed Mater Res. 23:1989;1483-1504
46. Cornelius R.M., Brash J.L. Identification of proteins adsorbed to hemodialyser membranes from heparinized plasma. J Biomater Sci Polym Ed. 4:1993;291-304
47. Matata B.M., Courtney J.M., Sundaram S., et al. Determination of contact phase activation by the measurement of the activity of supernatant and membrane surface-adsorbed factor XII. its relevance as a useful parameter for the in vitro assessment of haemodialysis membranes J Biomed Mater Res. 31:1996;63-70
48. Elam J-.H., Nygren H. Adsorption of coagulation proteins from whole blood on to polymer materials. relation to platelet activation Biomaterials. 13:1992;3-8
49. Van der Kamp K.W.H.J., van Oweren W. Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials. J Biomed Mater Res. 28:1994;349-352
50. Van der Kamp K.W.H.J., Kauch K.D., Feijen J., Horbett T.A. Contact activation during incubation of five different polyurethanes or glass in plasma. J Biomed Mater Res. 29:1995;1303-1306
51. Hong J., Nilsson Ekdahl K., Reynolds H., Larsson R., Nilsson B. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials. 20:1999;603-611
52. Blezer R., Willems G.M., Cahalan P.T., Lindhout T. Initiation and propagation of blood coagulation at artificial surfaces studied in a capillary flow reactor. Thromb Haemost. 79:1998;296-301
53. Irvine L., Sundaram S., Courtney J.M., Taggart D.P., Wheatley D.J., Lowe G.D.O. Monitoring of Factor XII activity and granulocyte elastase release during cardiopulmonary bypass. ASAIO Trans. XXXVII:1991;569-571
54. Boisclair M.D., Lane D.A., Philippou H. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 82:1993;3350-3357
55. Boisclair M.D., Philippou H., Lane D.A. Thrombogenic mechanisms in the human. fresh insights obtained by immunodiagnostic studies of coagulation markers Blood Coagul Fibrinolysis. 4:1993;1007-1021
56. Burman J.F., Chung H.I., Lane D.A., et al. Role of Factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet. 344:1994;1192-1193
57. Colman R.W. Mechanisms of thrombus formation. Cardiovasc Pathol. 2:1993;23S-31S
58. Ratner B.D. The blood compatibility catastrophe. J Biomed Mater Res. 27:1993;283-287
59. Edmunds L.H. Jr. Is prosthetic valve thrombogenicity related to design or material? Tex Heart Inst J. 23:1996;24-27
60. Chung J.H., Gikakis N., Rao K., Drake T.A., Colman R.W., Edmunds L.H.J. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 93:1996;2014-2018
61. Wilhelm C.R., Ristich J., Kormos R.L., Wagner W.R. Monocyte tissue factor expression and ongoing complement generation in ventricular assist devices patients. Ann Thorac Surg. 65:1998;1071-1076
62. Ernofsson M., Thelin S., Siegbahn A. Monocyte tissue factor expression, cell activation and thrombin formation during cardiopulmonary bypass. a clinical study J Thorac Cardiovasc Surg. 113:1997;576-584
63. Gorbet MB, Sefton MV. Leukocyte activation and procoagulant activities, in preparation.
64. Gorbet M.B., Sefton M.V. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets. J Biomed Mater Res. 67A:2003;792-800
65. Basmadjian D., Sefton M.V., Baldwin S.A. Coagulation on biomaterials in flowing blood. some theoretical considerations Biomaterials. 18:1997;1511-1522
66. Hirsh J., Weitz J.I. Antithrombin therapy. Califf R.M. Acute myocardial infarction and other acute ischemic syndromes. 1996;Mosby, St Louis
67. Hirsh J., Raschke R., Warkentin T.E., Dalen J.E., Deykin D., Poller L. Heparin. mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety Chest. 108:1995;258S-275S
68. Rubens F.D., Weitz J.I., Brash J.L., Kinlough-Rathbone R.L. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thromb Haemost. 69:1993;130-134
69. Gustafsson D., Elg M. The pharmacodynamics and pharmacokinetcis of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran. a mini-review Thromb Res. 109:2003;S9-S15
70. Edens R.E., Lindhart R.J., Weiler J.M. Heparin is not just an anticoagulant anymore. six and one-half decades of studies on the ability of heparin to regulate complement activity Complement Profiles. 1:1993;96-120
71. Misoph M., Schwender S., Babin-Ebell J. Response of the cellular immune system to cardiopulmonary bypass is independent of the applied pump type and of the use of heparin-coated surfaces. Thorac Cardiovasc Surg. 46:1998;222-227
72. Remes R., Williams D.F. Immune response in biocompatibility. Biomaterials. 13:1992;731-743
73. Hakim R.M. Complement activation by biomaterials. Cardiovasc Pathol. 2:1993;187S-197S
74. Kazatchkine M.D., Carreno M-.P. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials. 9:1988;30-35
75. Johnson R.J. Complement activation during extracorporeal therapy. biochemistry, cell biology and clinical relevance Nephrol Dial Transplant. 9:1994;36-45
76. Chenoweth D.E. Complement activation during hemodialysis. clinical observations, proposed mechanisms, and theoretical implications Artif Organs. 8:1984;281-290
77. Agostini A., Gardinali M. Complement activation during hemodialysis. J Biomater Appl. 4:1989;102-122
78. Videm V., Fosse E., Mollnes T.E., Garred P., Svennevig J.L. Time for new concepts about measurement of complement activation by cardiopulmonary bypass? Ann Thorac Surg. 54:1992;725-731
79. Kottke-Marchant K., Anderson J.M., Miller K.M., Marchant R.E., Lazarus H. Vascular graft-associated complement activation and leukocyte adhesion in an artificial circulation. J Biomed Mater Res. 21:1987;379-397
80. Shepard A.D., Gelfand J.A., Callow A.D., O'Donnell T.F. Jr. Complement activation by synthetic vascular grafts. J Vasc Surg. 1:1984;829-838
81. Johnson R.J. Immunology and the complement system. Ratner B.D., Hoffman A.S., Schoen F.J., Lemons J.E. Biomaterials science. 1996;173-188 Academic Press, San Diego
82. Craddock P.R., Fehr J., Dalmasso A.P., Brighan K.L., Jacob H.S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 59:1977;879-888
83. Tulunay M., Demiralp S., Tatsan S., et al. Complement (C3, C4) and C-reactive protein responses to cardiopulmonary bypass and protamine administration. Anaesth Intens Care. 21:1993;50-55
84. Lhotta K., Wurzner R., Kronenberg F., Opperman M., Konig P. Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int. 53:1998;1044-1051
85. Thylen P., Fernvik E., Lundhal J., Hed J., Jacobson S.H. Modulation of CD11b/CD18 on monocytes and neutrophils following hemodialysis membrane interaction in vitro. Int J Artif Organs. 19:1996;156-163
86. Nilsson U.R., Larm O., Nilsson B., Storm K.E., Elwing H., Nilsson Ekdahl K. Modification of the complement binding properties of polystyrene; effects of end-point heparin attachment. Scand J Immunol. 37:1993;349-354
87. Sefton M.V., Gemmell C.H., Gorbet M.B. What really is blood compatibility. J Biomater Sci Polym Ed. 11:2000;1165-1182
88. Gemmell C.H. Platelet adhesion onto artificial surfaces. inhibition by benzamidine, pentamidine, and pyridoxal-5-phosphate as demonstrated by flow cytometric quantification of platelet adhesion to microspheres J Lab Clin Med. 131:1998;84-92
89. Gemmell C.H. Activation of platelets by in vitro whole blood contact with materials. increases in microparticle, procoagulant activity, and soluble P-selectin blood levels J Biomater Sci Polym Ed. 12(8):2001;933-943
90. Gemmell C.H., Yeo E.L., Sefton M.V. Flow cytometric analysis of material-induced platelet activation in a canine model. elevated microparticle levels and reduced platelet life span J Biomed Mater Res. 37:1997;176-181
91. Blockmans D., Deckmyn H., Vermylen J. Platelet activation. Blood Rev. 9:1995;143-156
92. Marcus A.J. Platelet activation. Fuster V., Ross R., Topol E.J. Atherosclerosis and coronary artery disease. 1996;607-637 Lippincott-Raven Publishers, Philadelphia
93. Rinder H.M., Tracey J.L., Rinder C.S., Leitenberg D., Smith B.R. Neutrophil but not monocyte activation inhibits P-selectin-mediated platelet adhesion. Thromb Haemost. 72:1994;750-756
94. Rinder H.M., Bonan J.L., Rinder C.S., Ault K.A., Smith B.R. Dynamics of leukocyte-platelet adhesion in whole blood. Blood. 78:1991;1730-1737
95. Sims P.J., Wiedmer T. Induction of cellular procoagulant activity by the membrane attack complex of complement. Semin Cell Biol. 6:1995;275-282
96. Jy W., Mao W-.W., Horstman L.L., Tao J., Ahn Y.S. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis. 21:1995;217-231
97. Siljander P., Carpen O., Lassila R. Platelet derived microparticles associate with fibrin during thrombosis. Blood. 87:1996;4651-4663
98. Holme P.A., Solum N.O., Brosstad F., Pedersen T., Kveine M. Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregates with platelets. Thromb Haemost. 79:1998;389-394
99. Tans G., Rosing J., Christella M., et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 77:1991;2641-2648
100. Nieuwland R., Bercmans R.J., Rotteveel-Eijkman R.C., et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 96:1997;3534-3541
101. Gemmell C.H. Assessment of material-induced procoagulant activity by a modified Russell viper venom coagulation time test. J Biomed Mater Res. 42:1998;611-616
102. Ware J.A., Coller B.S. Platelet morphology, biochemistry and function. Beutler E., Lichtman M.A., Coller B.S., Kipps T.J. Williams hematology. 1995;1161-1225 McGraw-Hill, New York
103. Calvete J.J. Clues for understanding the structure and function of a prototypic human integrin. the platelet glycoprotein IIb/IIIa complex Thromb Haemost. 72:1994;1-15
104. van der Wieken L.R. Stents and IIb/IIIa receptor blockers combined. usefulness in various types of coronary artery disease Semin Interv Cardiol. 4:1999;77-83
105. Ellis S.G., Bates E.R., Schaible T., Weisman H.F., Pitt B., Topol E.J. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent postangioplasty restenosis and thrombosis. J Am Coll Cardiol. 17:1991;89B-95B
106. Mickelson J.K., Ali M.N., Kleiman N.S., et al. Chimeric 7E3 Fab (Reopro) decreases detectable CD11b on neutrophils from patients undergoing coronory angioplasty. J Am Coll Cardiol. 33:1999;97-106
107. Coller B.S., Anderson K.M., Weisman H.F. The anti-GPIIb/IIIa agents. fundamental and clinical aspects Haemostasis. 26:1996;285-293
108. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-61.
109. Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of Abciximab therapy in three randomized, placebo controlled trials of percutaneous coronary revascularization. Am J Med. 113:2002;1-6
110. Spinler S.A., Hilleman D.E., Cheng J.W.M., et al. New recommendations from the 1999 American College of CArdiology/American Heart Association acute myocardial infarction guidelines. Ann Pharmacotherapy. 35:2002;589-617
111. Cote A.V., Berger P.B., Holmes D.R. Jr., Scott C.G., Bell M.R. Hemorrhagic complications after percutaneous coronary interventions with adjunctive Abciximab. Mayo Clin Proc. 76:2002;890-896
112. Makoni S.N. Acute profound thrombocytopenia following angioplasty. the dilemma in the management and a review of the literature Heart. 86:2002;e18-e19
113. Grunkemeier J.M., Tsai W.B., Horbett T.A. Hemocompatibility of treated polystyrene substrates. contact activation, platelet adhesion, and procoagulant activity of adherent platelets J Biomed Mater Res. 41:1998;657-670
114. Godo M.N., Sefton M.V. Characterization of transient platelet contacts on a polyvinyl alcohol hydrogel by video microscopy. Biomaterials. 20:1999;1117-1126
115. Sheppard J.I., McClung W.G., Feuerstein I.A. Adherent platelet morphology on adsorbed fibrinogen. effects of protein incubation time and albumin addition J Biomed Mater Res. 28:1994;1175-1186
116. Chinn J.A., Ratner B.D., Horbett T.A. Adsorption of baboon fibrinogen and the adhesion of platelets to a thin film polymer deposited by radio-frequency glow discharge of allylamine. Biomaterials. 13:1992;322-332
117. Hanson S.R., Harker L.A. Blood coagulation and blood-materials interactions. Ratner B.D., Hoffman A.S., Schoen F.J., Lemons J.E. Biomaterials science. 1996;193-199 Academic Press, San Diego
118. Tsai W.B., Grunkemeier J.M., Horbett T.A. Human plasma fibrinogen adsorption and platelet adhesion to polystyrene. J Biomed Mater Res. 44:1999;130-139
119. Bailly A.L., Laurent A., Lu H., et al. Fibrinogen binding and platelet retention. relationship with the thrombogenicity of catheters J Biomed Mater Res. 30:1996;101-108
120. Gemmell C.H., Ramirez S.M., Yeo E.L., Sefton M.V. Platelet activation in whole blood by artificial surfaces. identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events J Lab Clin Med. 125:1995;276-287
121. Cholakis C.H., Zingg W., Sefton M.V. Effect of heparin-PVA hydrogel on platelets in a chronic canine AV shunt. J Biomed Mater Res. 23:1989;417-441
122. Hanson S.R., Harker L.A., Ratner B.D., Hoffman A.S. In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis. J Lab Clin Med. 95:1980;289-304
123. Ip W.F., Sefton M.V. Platelet consumption by NHLBI reference materials and silastic. J Biomed Mater Res. 25:1991;1321-1324
124. Hanson S.R., Harker L.A. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanisms independent of cyclooxygenase inhibition. J Clin Invest. 75:1999;1591-1599
125. Weily H.S., Steele P.P., Davies H., Pappas G., Genton E. Platelet survival inpatients with substitute heart valves. N Eng J Med. 290:1974;534-536
126. Llanos G.R., Sefton M.V. Immobilization of poly(ethylene glycol) onto poly(vinyl alcohol) hydrogel: 2. Evaluation of thrombogenicity. J Biomed Mater Res. 27:1993;1383-1391
127. Wachtfogel Y.T., Bischoff R., Bauer R., et al. Alpha 1-antitrypsin Pittsburgh (Met358→Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation. Thromb Haemost. 72:1994;843-847
128. Simon P., Ang K.S., Cam G. Enhanced platelet aggregation and membrane biocompatibility. possible influence on thrombosis and embolism in haemodialysis patients Nephron. 45:1987;172-173
129. Hakim R.M., Schafer Al. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med. 78:1985;575-580
130. Peerschke E.I.B., Ghebrehiwet B. Platelet receptors for the complement component C1q. implication for hemostasis and thrombosis Immunobiology. 199:1998;239-249
131. Bing D.H. Inhibition of guinea pig complement by aromatic amidine and guanidine compounds. J Immunol. 105:1970;1289-1291
132. Andrew J.M., Roman D.P. Jr., Bing D.H. Inhibition of four human serine proteases by substituted benzamidines. J Medicinal Chem. 21:1978;1202-1207
133. Hauptmann J., Markwardt F. Inhibition of the haemolytic complement activity by derivatives of benzamidine. Biochem Pharmacol. 26:1977;325-329
134. Cox D., Motoyama Y., Seki J., Aoki T., Dohi M., Yoshida K. Pentamidine. a non-peptide GPIIb/IIIa antagonist - in vitro studies on platelets from humans and other species Thromb Haemost. 68:1992;731-736
135. Cox D., Aoki T., Seki J., Motoyama Y., Yoshida K. Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Thromb Haemost. 75:1996;503-509
136. Allan R., Rodrick M., Knobel H.R., Isliker H. Inhibition of the interaction between the complement component C1q and immune complexes. Int Arch Allergy Appl Immunol. 58:1979;140-148
137. Subbarao K., Kuchubhotla J., Kakkar V.V. Pyridoxal 5′phosphate - a new physiological inhibitor of blood coagulation and platelet function. Biochem Pharmacol. 28:1979;531-534
138. Takada Y., Arimoto Y., Mineda H., Takada A. Inhibition of the classical and alternative pathways by amino acids and their derivatives. Immunology. 34:1978;509-515
139. Rinder C.S., Rinder H.M., Smith M.J., et al. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg. 118:1999;460-466
140. Rinder C.S., Rinder H.M., Smith B.R., et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 96:1995;1564-1572
141. Gorbet MB, Sefton MV. Role of complement and platelets in leukocyte activation induced by polystyrene and PEG-immobilized polystyrene beads in whole blood. J Biomed Mater Res, in preparation.
142. Larsson R., Elgue G., Larsson A., Ekdahl K.N., Nilsson U.R., Nilsson B. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit. reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface Immunopharmacology. 38:1997;119-127
143. Cassatella M.A. The production of cytokines by PMN. Immunol Today. 16:1995;21-26
144. Anderson J.M. Mechanisms of inflammation and infection with implanted devices. Cardiovasc Pathol. 2:1993;33S-41S
145. Del Maschio A., Corvazier E., Maillet F., Kazatchkine M.D., Maclouf J. Platelet dependent induction and amplification of polymorphonuclear leukocyte lysosomal enzyme release. Br J Haematol. 72:1989;329-335
146. Bazzoni G., Dejana E., Del Maschio A. Platelet-dependent modulation of neutrophil function. Pharmacol Res. 26:1992;269-272
147. Del Maschio A., Dejana E., Bazzoni G. Bidirectional modulation of platelet and polymorphonuclear leukocyte activities. Ann Hematol. 67:1993;23-31
148. Rebuck N., Finn A. Polymorphonuclear granulocyte expression of CD11a/CD18, CD11b/CD18 and L-selectin in normal individuals. FEMS Immunol Med Microbiol. 8:1994;189-196
149. Camerer E., Kolsto A-.B., Pridz H. Cell biology of tissue factor, the principal initiator of coagulation. Thromb Res. 81:1996;1-41
150. Smith J.A. Neutrophils, host defense, and inflammation; a double-edged sword. J Leukocyte Biol. 56:1994;686
151. Kuijipers T.W., Hakkert B.C., Van Mourik J.A., Roos D. Distinct adhesive properties of granulocytes and monocytes to endothelial cells under static and stirred conditions. J Immunol. 145:1990;2588-2594
152. van Ginkel C.J.W., van Haken W.G., Oh J.I.H., Vreeken J. Stimulation of monocyte procoagulant activity by adherence to different surfaces. Br J Haematol. 37:1977;35-45
153. Gorbet M.B., Yeo E.L., Sefton M.V. Flow cytometric study of in vitro neutrophil activation by biomaterials. J Biomed Mater Res. 44:1999;289-297
154. Ginis I., Tauber A.I. Activation mechanisms of adherent human neutrophils. Blood. 76:1990;1233-1239
155. Jones D.A., Smith C.W., McIntire L.V. Leukocyte adhesion under flow conditions. principles important in tissue engineering Biomaterials. 17:1996;337-347
156. Butcher E.C. Leukocyte-endothelial cell recognition. three or (more) steps to specificity and diversity Cell. 67:1991;1033-1036
157. Arnaout M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 75:1990;1037-1050
158. Philips M.R., Buyon J.P., Winchester R., Weissmann G., Abramson S.B. Upregulation of the iC3b receptor is neither necessary nor sufficient to promote neutrophil aggregation. J Clin Invest. 82:1988;495-501
159. 2 integrin CD11b/CD18 upregulation on neutrophils and monocytes after coronary artery bypass grafting. Scand J Thorac Cardiovasc Surg. 30:1996;141-148
160. Serrano C.V., Ramires J.A., Venturinelli M., et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecules expression. J Am Coll Cardiol. 29:1997;1276-1283
161. Inque T., Sakai Y., Morooka S., Hayashi T., Takayanagi K., Takabatake Y. Expression of polymorphonuclear adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 28:1996;1127-1133
162. Neumann F.J., Ott I., Gawaz M., Puchner G., Schömig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol. 27:1996;819-824
163. Rousseau Y., Carreno M-.P., Poignet J-.L., Kaztchkine M.D., Haeffner-Cavaillon N. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials. 20:1999;1959-1967
164. Cristol J.P., Canaud B., Rabesandratana H., Gaillard I., Serre A., Mion C. Enhancement of reactive oxygen species production and cell surface markers expression due to hemodialysis. Nephrol Dial Transplant. 9:1994;389-394
165. Von Appen K., Goolsby C., Mehl P., Goewert R., Ivanovich P. Leukocyte adhesion molecule as biocompatibility markers for hemodialysis membranes. ASAIO J. 40:1994;M609-M615
166. Rinder C., Fitch J. Amplification of the inflammatory response. adhesion molecules associated with platelet/white cell responses J Cardiovasc Pharmacol. 27(Suppl. 1):1996;S6-S12
167. El Habbal M.H., Carter H Smith L., Elliot M.J., Strobel S. Neutrophil activation in paediatric extracorporeal circuits. effect of circulation and temperature variation Cardiovasc Res. 29:1995;102-107
168. Gillinov A.M., Bator J.M., Zehr K.J., et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg. 56:1993;847-853
169. Cameron D.E. Initiation of white cell activation during cardiopulmonary bypass. cytokines and receptors J Cardiovasc Pharmacol. 27:1996;S1-S5
170. Asimakopoulos G., Taylor K.M. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg. 66:1998;2135-2144
171. Horl W.H., Riegel W., Steinhauer H.B., et al. Granulocyte activation during hemodialysis. Clin Nephrol. 26:1986;S30-S34
172. Grooteman M.P., van T.A., van H.A., et al. Hemodialysis-induced degranulation of polymorphonuclear cells. no correlation between membrane markers and degranulation products Nephron. 85:2000;267-274
173. Haag-Weber M., Schollmeyer P., Horl W.H. Beta-2-microglobulin and main granulocyte components in hemodialysis patients. Artif Organs. 13:1989;92-96
174. Stegmayr B.G., Esbensen K., Gutierrez A., et al. Granulocyte elastase, β thromboglobulin, and C3d during acetate or bicarbonate hemodialysis with hemophan compared to a cellulose acetate membrane. Int J Artif Organs. 15:1992;10-18
175. Wachtfogel Y.T., Kucich U., Greenplate J., et al. Human neutrophil degranulation during extracorporeal circulation. Blood. 69:1987;324-330
176. Peek G.J., Firmin R.K. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J. 45:1999;250-263
177. Frering B., Philip I., Dehoux M., Rolland C., Langlois J.M., Desmont J.M. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg. 108:1994;636-641
178. Himmelfarb J., Lazarus J.M., Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis. XVII:1991;271-276
179. Kaplan S.S., Basford R.E. Mechanisms of biomaterial induced superoxide release by neutrophils. J Biomed Mater Res. 28:2000;377-386
180. Kuwahara T., Markert M., Wauters J.P. Proteins adsorbed on hemodialysis membranes modulate neutrophil activation. Artif Organs. 13:1989;427-431
181. Serruys P.W., Strauss B.H., van Beusekom H.M., van der Giessen W.J. Stenting of coronary arteries. has a modern Pandora's box been opened J Am Coll Cardiol. 17:1991;143B-154B
182. van Beusekom H.M.M., van der Giessen W.J., Van Suylen R.J., Bos E., Bosman F.T., Serruys P.W. Histology after stenting of human saphenous vein bypass grafts. observations from surgically excised grafts 3-320 days after stent implantation J Am Coll Cardiol. 21:1993;45-54
183. Jobes D.R. Safety issues in heparin and protamine administration for extracorporeal circulation. J Cardiothorac Vasc Anesth. 12:1998;17-20
184. Grooteman M.P.C., Bos J.C., Van Houte A.J., van Limbeek J., Schoorl M., Nube M.J. Mechanisms of intra-dialyser granulocyte activation. a sequential dialyser elution study Nephrol Dial Transplant. 12:1997;492-499
185. Castiglione A, Pagliaro P, Romagnoni M, Beccari M, Cavaliere G, Veneroni G. Flow cytometric analysis of leukocytes eluted from haemodialysers. Nephrol Dial Transplant 1991;(Suppl. 2):31-35.
186. Gemmell C.H., Black J.P., Yeo E.L., Sefton M.V. Material-induced up-regulation of leukocyte CD11b during whole blood contact. material differences and a role for complement J Biomed Mater Res. 32:1996;29-35
187. Gorbet M.B., Sefton M.V. Expression of procoagulant activities on Leukocytes following contact with polystyrene and PEG grafted polystyrene beads. J Lab Clin Med. 137:2001;345-355
188. Kao W.J., Sapatnekar S., Hiltner A., Anderson J.M. Complement-mediated leukocyte adhesion on poly(etherurethane ureas) under shear stress in vitro. J Biomed Mater Res. 32:1996;99-109
189. McNally A.K., Anderson J.M. Complement C3 participation in monocyte adhesion to different surfaces. Proc Natl Acad Sci USA. 91:1994;10119-10123
190. Cheung A.K., Hohnholt M., Gilson J. Adherence of neutrophils to haemodialysis membranes. roles of complement receptors Kidney Int. 40:1991;1123-1133
191. Tang L., Lucas A.H., Eaton J.W. Inflammatory responses to implanted polymeric biomaterials. role of surface adsorbed immunoglobulin G J Lab Clin Med. 122:1993;292-300
192. Tang L., Eaton J.W. Fibrinogen mediates acute inflammatory responses to biomaterials. J Exp Med. 178:1993;2147-2156
193. Eriksson O., Nygren H. Polymorphonuclear leukocytes in coagulating whole blood recognize hydrophilic and hydrophobic titanium surfaces by different adhesion receptors and show different patterns of receptor expression. J Lab Clin Med. 137:2001;296-302
194. Gemmell C.H. Flow cytometric evaluation of material-induced platelet and complement activation. J Biomater Sci Polym Ed. 11(11):2000;1197-1210
195. Morley D.J., Feuerstein I.A. Adhesion of polymorphonuclear leukocytes to protein-coated and platelet adherent surfaces. Thromb Haemost. 62:1989;1023-1028
196. Herzlinger G.A., Cumming R.D. Role of complement activation in cell adhesion to polymer blood contact surfaces. ASAIO Trans. XXXVI:1980;165-171
197. Wachtfogel Y.T., Kettner C., Hack C.E., et al. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation. Thromb Haemost. 80:1998;686-691
198. Wachtfogel Y.T., Kucich U., Hack C.E., et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 106:1993;1-9
199. Himmelfarb J., Holbrook D., McMonagle E. Effects of aprotinin on complement and granulocyte activation during ex vivo hemodialysis. Am J Kidney Dis. 24:1994;901-906
200. Himmelfarb J., McMonagle E., Holbrook D., Toth C. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis. J Lab Clin Med. 126:1995;392-400
201. Gillinov A.M., Redmond J.M., Winkelstein J.A., et al. Complement and neutrophil activation during cardiopulmonary bypass. a study in the complement-deficient dog Ann Thorac Surg. 57:1994;345-352
202. Finn A., Morgan B.P., Rebuck N., et al. Effects of inhibition of complement activation using recombinant soluble receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. J Thorac Cardiovasc Surg. 111:1996;451-459
203. Rinder C.S., Rinder H.M., Johnson K., et al. Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation. 100:1999;553-558
204. Gorbet MB, Sefton MV. The importance of platelets and complement in material-induced Leukocyte activation in vitro. PhD Thesis, University of Toronton, 2001.
205. Kappelmayer J., Bernabei A., Edmunds L.H. Jr., Edgington T.S., Colman R.W. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 72:1993;1075-1081
206. Barstad R.M., Hamers M.J.A.G., Moller A-.S., Sakariassen K.S. Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin coating of the surface. Thromb Haemost. 79:1998;302-305
207. Stahl R.F., Fisher C.A., Kucich U., et al. Effects of simulated extracorporeal circulation on human leukocyte elastase release, superoxide generation and procoagulant activity. J Thorac Cardiovasc Surg. 101:1991;230-239
208. Parratt R., Hunt B.J. Direct activation of factor X by monocytes occurs during cardiopulmonary bypass. Br J Haematol. 101:1998;40-46
209. Rinder C.S., Bonan J.L., Rinder H.M., Mathew J., Hines R., Smith B.R. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood. 79:1992;1201-1205
210. Gawaz M., Bogner C. Changes in platelet membrane glycoproteins and platelet leukocyte interactions during hemodialysis. J Clin Invest. 72:1994;424-429
211. May A.E., Neumann F-.J., Gavaz M., Ott I., Walter H., Schömig A. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur Heart J. 18:1997;1913-1920
212. Palabrica T., Lobb R., Furie B.C., et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 359:1992;848-851
213. Toombs C.F., De Graaf G.L., Martin J.P., Geng J.G., Anderson D.C., Shebuski R.J. Pretreatment with a blocking antibody to P-sel accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharmacol Exp Ther. 275:1995;941
214. Turitto V.T., Weiss H.J., Baumgartner H.R. The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood. Microvasc Res. 19:1980;352-365
215. Turitto V.T., Hall C.L. Mechanical factors affecting hemostasis and thrombosis. Thromb Res. 92:1998;S25-S31
216. Hanson S.R., Sakariassen K.S. Blood flow and antithrombotic drug effects. Am Heart J. 135:1998;S132-S145
217. O'Brien J.R. Shear induced platelet aggregation. Lancet. 335:1990;711-713
218. Oda A., Yokoyama K., Murata M., et al. Protein tyrosine phosphorylation in human platelets during shear-stress induced aggregation (SIPA) is regulated by GPIb/IX as well as GPIIb/IIIa and requires intact cytoskeleton and endogenous ADP. Thromb Haemost. 74:1995;736-742
219. Kujiper P.H.M., Gallardo Torres H.I., van der Linden J.A.M., et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood. 87:1996;3271-3281
220. Yeo E.L., Sheppard J-.O.I., Feuerstein I.A. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiological shear conditions (an injury vessel wall model). Blood. 83:1994;2498-2507
221. Weber C., Springer T.A. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of MAc-1 with fibrinogen bound to αIIbβ3 and stimulated by platelet activating factor. J Clin Invest. 100:1997;2085-2093
222. Kujiper P.H.M., Gallardo Torres H.I., Lammers J-.W.J., Sixma J.J., Koenderman L., Zwaginga J.J. Platelet and fibrin deposition at the damaged vessel wall. cooperative substrates for neutrophil adhesion under flow conditions Blood. 89:1997;166-175
223. Bruil A, Sheppard JI, Feijen J, Feuerstein IA. In vitro leukocyte adhesion to modified polyurethane surfaces: III Effects of flow, fluid medium and platelets on PMN adhesion. In: Cooper SL, Bamford CH, Tsuruta T, editors. Polymer biomaterials in solution, as interfaces and as solid. Zeist, The Netherlands: VSP; 1995. p. 357-71.
224. Kujiper P.H.M., Gallardo Torres H.I., van der Linden J.A.M., et al. Neutrophil adhesion to fibrinogen and fibrin under flow conditions is diminished by activation and L-selectin shedding. Blood. 89:1997;2131-2138
225. Hernandez M.R., Escolar G., Bozzo J., Galan A.M., Ordinas A. Inhibition of fibrin deposition on the subendothelium by a monoclonal antibody to polymorphonuclear leukocyte integrin CD11b. Studies in a flow system. Haematologica. 82:1997;566-571
226. Bahra P., Nash G.B. Sparsely adherent platelets support capture and immobilization of flowing neutrophils. J Lab Clin Med. 132:1998;223-228
227. Gemmell C.H., Nemerson Y., Turitto V.T. The effects of shear rate on the enzymatic activity of the tissue factor-factor VIIa complex. Microvasc Res. 40:1990;327-340
228. Nemerson Y., Contino P.B. Tissue factor, flow and the initiation of coagulation. Seghatchian M.J., Samana M.M., Hecker S.P. Hypercoagulable states. 1996;21-28 CRC Press, Boca Raton, FL
229. Bluestein D., Rambod E., Gharib M. Vortex shedding as a mechanism for free emboli formation in mechanical heart valves. J Biomech Eng. 122:2000;125-134
230. Melder R.J., Munn L.L., Yamada S., Ohkubo C., Jain R.K. Selectin and integrin-mediated T lymphocyte rolling and arrest on TNF-α activated endothelium. augmentation by erythrocytes Biophys J. 69:1995;2131-2138
231. Lynn W.A., Golenbock D.T. Lipopolysaccharide antagonists. Immunol Today. 13:1992;271-276
232. Lemke H.D. Methods for the detection of endotoxins present during extracorporeal circulation. Nephrol Dial Transplant. 9:1994;90-95
233. US Department of Health and Human Services/Public Health Services/Food and Drug Administration. Guideline on validation of the limulus amebocyte lysate test as an end-product endotoxin test for human and animal parental drugs, biological products and medical devices. 1987. p. 1-30. Available at http://www.fda.gov/cber/gdlns/lal.pdf
234. Hirthler M., Simoni J., Dickson M. Elevated levels of endotoxin, oxygen-derived free radicals and cytokines during extracorporeal membrane oxygenation. J Pediatr Surg. 27:1992;1199-1202
235. Nilsson L., Kulander L., Nyström S-.O., Eriksson O. Endotoxin in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 100:1990;777-780
236. Butler J., Rocker G.M., Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;552-559
237. Khabar K.S., elBarbary M.A., Khouqeer F., Devol E., al-Gain S., al-Halees Z. Circulating endotoxin and cytokines after cardiopulmonary bypass. differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndrome Immunol Immunopathol. 85:1997;97-103
238. Rocke D.A., Gaffin S.L., Wells M.T., Koen Y., Brock Utine J.G. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 93:1987;832-837
239. Laude-Sharp M., Caroff M., Simard L., Pusineri C., Kazatchkine M.D., Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis. transmembrane passage of intact endotoxin (LPS) Kidney Int. 38:1990;1089-1094
240. Khazazmi A., Andersen L.W., Baek L., Valerius N.H., Laub M., Rasmussen J.P. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 98:1989;381-385
241. Casko G., Suba E.A., Elin R.J. Endotoxin-induced platelet activation in human whole blood in vitro. Thromb Haemost. 59:1988;375-382
242. Weingarten R., Sklar L.A., Mathison J.C., et al. Interactions of lipopolysaccharide with neutrophils in blood via CD14. J Leukocyte Biol. 53:1993;518-524
243. Wright S.D., Ramos R.A., Hermanowski-Vosatka A., Rockwell P., Detmers P.A. Activation of the adhesive capacity of CR3 on neutrophils by endotoxin. dependence on lipopolysaccharide binding protein and CD14 J Exp Med. 173:1991;1281-1286
244. Pearson F.C. A comparison of the pyrogenicity of environmental endotoxins and lipopolysaccharides. Ten Cate J.W., Büller H.R., Sturk A., Levin J. Bacterial endotoxins: structure, biomedical significance, and detection with the Limulus Amebocyte Lysate test. 1985;251-263 Alan Riss, Inc, New York
245. Enders G., Brooks W., Von Jan N., Lehn N., Bayerdörfer E., Hatz R. Expression of adhesion molecules on human granulocytes after stimulation with Helicobacter pylori membrane proteins. comparison with membrane proteins from other bacteria Infect Immun. 63:1995;2473-2477
246. Tielemans C., Husson C., Schurmans T., et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int. 49:1996;236-243
247. Ragab A.A., Van de Motter R., Lavish S.A., et al. Measurement and removal of adherent endotoxin from Titanium particles and implant surfaces. J Orthop Res. 17:1999;803-809
248. Hitchins V.M., Merritt K. Decontaminating particles exposed to bacterial endotoxin (LPS). J Biomed Mater Res. 46:1999;434-437
249. Gillis S., Furie B.C., Furie B. Interactions of neutrophils and coagulation proteins. Semin Hematol. 34:1997;336-342
250. Altieri D.C. Inflammatory cell participation in coagulation. Semin Cell Biol. 6:1995;269-274
251. Esmon C.T. Introduction. cellular regulation of blood coagulation Semin Cell Biol. 6:1995;257-258
252. May A.E., Neumann F.J., Preissner K.T. The relevance of blood-cell wall adhesive interactions for vascular thrombotic disease. Thromb Haemost. 82:1999;962-970
253. Marcus A.J. Thrombosis and inflammation as multicellular processes. significance of cell-cell interactions Semin Hematol. 31:2000;261-269
254. Sengelov H. Complement receptors in neutrophils. Crit Rev Immunol. 15:1995;107-131
255. Pabst M.J. Priming of neutrophils. Hellewell P.G., Williams T.J. Immunopharmacology of the neutrophil. 1994;195-222 Academic Press, London
256. Sims P.J. Interaction of platelets with complement system. Kunicki T.J., Georges J.N. Platelet immunobiology: molecular and clinical aspects. 1989;354-383 Lippincott, Philadelphia
257. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology. 38:1997;51-62
258. Hitchins V.M., Merritt K. Decontaminating particles exposed to bacterial endotoxin (LPS). J Biomed Mater Res. 46:1999;434-437
259. Ragab A.A., Van de Motter R., Lavish S.A., Goldberg V.M., Ninomiya J.T., Carlin C.R., Greenfield E.M. Measurement and removal of adherent endotoxin from titanium particles and implant surfaces. J Orthop Res. 17:1999;803-809